NCT04225364View on ClinicalTrials.gov

Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 17, 2020

Primary Completion Date

January 15, 2021

Study Completion Date

January 31, 2021

Conditions
Esophageal Squamous Cell CarcinomaImmunotherapy
Interventions
DRUG

camrelizumab

Participants will receive camrelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.

DRUG

Paclitaxel for injection (albumin-bound)

Paclitaxel for injection (albumin-bound): 260mg/m2(in total), ivgtt d1, d8, q3w，for 2 cycle

DRUG

Cisplatin

75mg/m2(in total), ivgtt d1-d3, q3w, for 2 cycles

Trial Locations (1)

Unknown

Jingpei Li, Guangzhou

All Listed Sponsors
collaborator

BGI-Shenzhen

INDUSTRY

collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Guangzhou Institute of Respiratory Disease

OTHER

NCT04225364 - Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter